2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 59

Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Abstract Number: 60

mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA
Abstract Number: 61

Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency
Abstract Number: 62

Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Abstract Number: 63

The Role of the Intestinal Microbiota in Lupus Nephritis
Abstract Number: 64

Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice
Abstract Number: 65

CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Abstract Number: 66

Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Abstract Number: 67

Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model
Abstract Number: 68

Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 69

Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Abstract Number: 70

Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment
Abstract Number: 71

Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival
Abstract Number: 72

The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Abstract Number: 73

Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome

« Previous Page
1
…
5
6
7
8
9
…
198
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].